BGLC · XBRL financial data

BioNexus Gene Lab financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BGLC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	11,390	13,363	10,929	9,771	9,511	7,425
Cost of revenue	9,671	11,169	9,670	8,441	8,221	6,340
Gross profit	1,720	2,194	1,259	1,329	1,290	1,085
Research and development	—	—	—	55	48	51
General and administrative	1,333	1,204	1,729	4,409	1,974	1,535
Total operating expenses	—	—	—	(4,409)	(4,936)	4,482
Operating income (loss)	1,274	1,056	(291)	(2,594)	(1,574)	(2,965)
Interest expense	—	—	12	14	—	—
Other income (expense)	—	—	—	486	2,072	432
Income tax expense (benefit)	—	(291)	(52)	(22)	(3)	0
Net income (loss)	1,094	752	(356)	(2,629)	(1,598)	(2,985)
Earnings per share, diluted USD per share	—	—	—	(0.17)	(0.09)	—
Weighted average shares, diluted thousands of shares	—	—	—	15,875	17,818	—

† Share count changed about 1/10 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BGLC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,788	2,124	2,119	5,929	2,887	2,486
Accounts receivable	—	—	—	—	1,377	506
Inventory	1,176	1,522	978	1,138	1,389	677
Total current assets	7,985	7,150	6,022	8,047	7,430	5,449
Property and equipment, net	1,786	1,634	1,512	1,512	1,523	1,599
Right-of-use asset	63	41	56	142	215	178
Total assets	10,115	9,574	8,740	11,400	10,434	9,253
Accounts payable	—	2,012	1,861	1,402	1,503	—
Accrued liabilities	—	—	—	—	169	126
Total current liabilities	3,374	2,329	2,004	1,631	1,951	521
Lease liability, non-current	42	13	40	99	160	117
Total liabilities	3,453	2,395	2,075	1,742	2,111	638
Retained earnings (accumulated deficit)	761	1,512	1,156	(1,844)	(3,443)	(6,427)
Total stockholders' equity	6,662	7,180	6,665	9,658	8,323	8,615
Total liabilities and equity	10,115	9,574	8,740	11,400	10,434	9,253
Common shares outstanding (cover page) thousands of shares	171,218	171,218	173,718	17,668	17,968	2,417

† Share count changed about 1/10 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BGLC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,094	752	(356)	(2,629)	(1,598)	(2,985)
Stock-based compensation	—	—	—	—	141	795
Net cash from operating activities	553	9	544	(1,302)	(2,234)	(1,838)
Purchases of property and equipment	422	3	54	0	227	37
Net cash from investing activities	1,320	(491)	(450)	(383)	418	945
Proceeds from issuing equity	—	—	—	—	—	267
Net cash from financing activities	(5)	(28)	116	5,754	145	299
Net change in cash	—	(664)	(5)	3,810	(1,631)	(401)

† Share count changed about 1/10 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
BioNexus Gene Lab	1,233	76	(422)*	2.9M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Aclarion	16,285	25	(2,657)*	2.9M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Advanced Biomed	386	year only	(583)*	1.7M	0.7 quarters	Q4 FY26 10-KJun 30, 2026
Ludwig Enterprises	18	not reported	(153)	167.2M	1.3 quarters	Q1 FY26 10-QMar 31, 2026
CapForce	144	50,000	(618)*	12.4M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
American Shared Hospital Services	6,511	8,430	2,236*	6.7M	—	Q2 FY26 10-QJun 30, 2026
Biodesix	29,996	26,861	(1,562)*	10.6M	19.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.